摘要
1例71岁男性患者因脑梗死急性期、室性早搏、高同型半胱氨酸血症入院,给予疏血通注射液6 ml、醒脑静注射液20 ml、吡拉西坦注射液250 ml静脉滴注,1次/d;阿司匹林0.1 g、叶酸5 mg、甲钴胺500μg口服,1次/d。因动脉血管超声示双侧颈动脉粥样硬化,故给予阿托伐他汀钙10 mg,1次/d口服。入院时患者肌酸激酶(CK)90 U/L,服用阿托伐他汀钙第3天升至777 U/L,第6天为1332 U/L,尿液呈浅棕色,尿潜血(+)。停服阿托伐他汀钙,其他治疗无改变,第2天CK降至1126 U/L,第7天降至129 U/L,尿液呈浅黄色,尿潜血(-)。
A 71-year-old man was hospitalized with acute cerebral infarction, ventricular premature beats and hyperhomoeysteinemia. He received an IV infusion of Shuxuetong （疏血通） injection 6 ml, Xingnaojing （性脑筋） injection 20 ml and piracetam injection 250 ml once daily, and oral administration of aspirin 0. 1 g, folie acid 5 mg and mecobalamin 500μg once daily. In addition, the patient received atorvastatin calcium 10 mg once daily for bilateral carotid atherosclerosis which was diagnosed using uhrasonography. His creatine kinase（CK） was 90 U/L on admission and was increased to 777 U/L and 1332 U/L on days 3 and 6 of atorvastatin calcium therapy, respectively. The dark urine appeared and urinary occult blood test was positive. Atorvastatin calcium was withdrawn and other treatment was unchanged. The CK level was decreased to 1126 and 129 U/L on days 3 and 7 of drug withdrawal, respectively. The urine became light yellow in color and urine occult blood test was negative.
出处
《药物不良反应杂志》
2012年第1期45-47,共3页
Adverse Drug Reactions Journal
关键词
肌酸激酶
阿托伐他汀钙
creatine kinase
atorvastatin calcium
